Company profile

BioXcel Therapeutics, Inc.

Pipeline6 assets

BXCL501BXCL501 / IGALMI / alpha-2 receptor agonist / orally dissolving/sublingual film formulation of dexmedetomidine / Neuroscience
Acute agitation associated with bipolar disorders or schizophrenia, at homePhase 3Company-sponsored SERENITY programAcute agitation associated with Alzheimer's dementiaPhase 3Company-sponsored TRANQUILITY program; paused subject to fundingOpioid use disorderPhase 2Investigator-sponsored
BXCL701BXCL701 / DPP8/9 and FAP / oral innate immune activator / Immuno-oncology
Small cell neuroendocrine prostate cancerPhase 2Company-sponsored; FDA meeting expectedUSUKSmall cell lung cancerPreclinicalCompany-sponsored; initiate Phase 1b/2 expectedMetastatic pancreatic ductal adenocarcinomaPhase 2Investigator-sponsored; Phase 2 readout expected
BXCL502BXCL502 / latrepirdine / Neuroscience
Chronic agitation in dementiaPreclinicalDevelopment paused due to strategic reprioritization
BXCL503BXCL503 / Neuroscience
Apathy in dementiaPreclinicalDevelopment paused due to strategic reprioritization
BXCL504BXCL504 / Neuroscience
Aggression in dementiaPreclinicalDevelopment paused due to strategic reprioritization
BXCL702BXCL702 / DPP inhibitor / novel DPP inhibitor / Immuno-oncology
Solid tumorsPreclinicalBXCL701 follow-on; candidate nomination expected

Latest news4 items

Aug 28, 2026

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process BioXcel Therapeutics has secured a commitment for debtor-in-possession

May 28, 2026

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY

Presentation / Abstract • Phase 3Poster presentation Thu, May 28, 2026, 11:30 AM

May 15, 2026

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the

Apr 17, 2026

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial